Form 4 for BDX Becton Dickinson
Accepted 2023-08-14 00:00:00 ET · period of report 2023-08-11 · accession 0001062993-23-016439 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-14 | 2023-08-11 | BDX | Hickey David | EVP, Pres, Life Sciences | D - Sale to Iss | $277.85 | -1,857 | 7,173 | -21% | -$516.0K |
| D | 2023-08-14 | 2023-08-11 | BDX | Hickey David | EVP, Pres, Life Sciences | M - OptEx | $132.54 | +3,883 | 9,030 | +75% | +$514.7K |
| D | 2023-08-14 | 2023-08-11 | BDX | Hickey David | EVP, Pres, Life Sciences | S - Sale+OE | $277.85 | -2,974 | 4,199 | -41% | -$826.3K |
| D | 2023-08-14 | 2023-08-11 | BDX | Hickey David | EVP, Pres, Life Sciences | M - OptEx | $0.00 | -3,883 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-11 | D | D | 1,857 | $277.85 | 7,173 | D | — | — | |
| 2 | Common | Common Stock | 2023-08-11 | M | A | 3,883 | $132.54 | 9,030 | D | — | — | |
| 3 | Common | Common Stock | 2023-08-11 | S | D | 2,974 | $277.85 | 4,199 | D | — | — | (F1) The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $277.41 to $280.00. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder upon request. |
| 4 | Derivative | Stock Appreciation Rights | 2023-08-11 | M | D | 3,883 | $0.00 | 0 | D | $132.54 · 2015-11-25 to 2024-11-25 | 3,883 Common Stock | (F2) Award terms reflect adjustments made in connection with the spin-off of Embecta Corp. (F3) The stock appreciation rights vest in four annual installments beginning November 25, 2015. |